TYK2/JAK1抑制剂PF-06700841在斑块状银屑病中减少皮肤炎症的分子与细胞反应
该临床研究纳入30例中重度斑块状银屑病患者,随机接受PF-06700841 30mg(n=14)、100mg(n=7)或安慰剂(n=9)每日一次治疗28天,并在基线及第2、4周取皮损与非皮损活检。结果显示IL-17A、IL-17F和IL-12B mRNA在2周内下降,4周时皮损基因表达约70%恢复正常,角质形成细胞活化标志、表皮厚度及T细胞和树突状细胞浸润显著减少,组织学评分改善。
要点
- PF-06700841可早期抑制IL-17/IL-23相关炎症基因表达。
- 治疗4周后皮损基因表达约70%恢复正常。
- 2周内角质形成细胞活化与免疫细胞浸润显著减少。
核心结论
- PF-06700841通过抑制依赖TYK2和JAK1信号转导的促炎细胞因子改善慢性斑块状银屑病临床症状。
研究设计与样本
- 随机对照临床研究,30例中重度斑块状银屑病患者随机接受PF-06700841 30mg(n=14)、100mg(n=7)或安慰剂(n=9)每日一次治疗28天。
- 于基线及第2、4周取非皮损与皮损皮肤活检,用微阵列和逆转录PCR评估银屑病转录组及IL-17诱导的角质形成细胞基因。
主要发现
- IL-17A、IL-17F和IL-12B mRNA在治疗2周内即出现下降。
- 治疗4周后皮损基因表达约70%恢复正常。
- 免疫组化显示治疗2周后角质形成细胞活化标志、表皮厚度、KRT16和Ki-67表达及CD3+/CD8+ T细胞和CD11c树突状细胞浸润显著减少,并与组织学评分改善对应。
临床怎么用
- PF-06700841可快速抑制银屑病皮损中IL-17/IL-23相关炎症通路,支持其作为斑块状银屑病的潜在靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The IL-23/T helper type 17 cell axis is a target for psoriasis. The TYK2/Janus kinase 1 inhibitor PF-06700841 will directly suppress TYK2-dependent IL-12 and IL-23 signaling and Janus kinase 1-dependent signaling in cells expressing these signaling molecules, including T cells and keratinocytes. This clinical study sought to define the inflammatory gene and cellular pathways through which PF-06700841 improves the clinical manifestations of psoriasis. Patients (n = 30) with moderate-to-severe psoriasis were randomized to once-daily 30 mg (n = 14) or 100 mg (n = 7) PF-06700841 or placebo (n = 9) for 28 days. Biopsies were taken from nonlesional and lesional skin at baseline and weeks 2 and 4. Changes in the psoriasis transcriptome and genes induced by IL-17 in keratinocytes were evaluated with microarray profiling and reverse transcriptase-PCR. Reductions in IL-17A, IL-17F, and IL-12B mRNA were observed as early as 2 weeks and approximately 70% normalization of lesional gene expression after 4 weeks. Immunohistochemistry showed significant decreases in markers of keratinocyte activation, epidermal thickness, KRT16 and Ki-67 expression, and immune cell infiltrates CD3+/CD8+ (T cells) and CD11c (dendritic cells) after 2 weeks of treatment, corresponding with improvement in histologic score. PF-06700841 improves clinical symptoms of chronic plaque psoriasis by inhibition of proinflammatory cytokines that require TYK2 and Janus kinase 1 for signal transduction.
引用
- Page KM, Suarez-Farinas M, Suprun M, et al. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. J Invest Dermatol. 2020. PMID: 31972249. doi:10.1016/j.jid.2019.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。